Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371032 | 1.00 | HTR3A (0.63) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219431 | 0.85 | HTR3A (0.63) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6218364 | 0.79 | HTR3A (0.81) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6375585 | 0.79 | HTR3A (0.55) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219132 | 0.78 | HTR3A (1.00) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219110 | 0.78 | HTR3A (0.55) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219108 | 0.78 | HTR3A (0.55) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27627894 | 0.78 | MAPK14 (0.44) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27627887 | 0.78 | MAPK14 (0.44) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6245573 | 0.75 | HTR3A (0.74) | HTR3AMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549635-A1 | 3,4-DISUBSTITUTED PYRROLES AND THEIR FOR USE IN TREATING INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-06 | — | — | EP | disclosed |
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2004029040-A1 | 3,4-DISUBSTITUTED PYRROLES AND THEIR FOR USE IN TREATING INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | TNF, TSLP, IRAK1 | HTR3A 2032/4885MAPK14 240/4885MAPK13 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.